Value proposition

Addressing "undruggable"​ oncology targets by delivering whole antibodies inside the tumor and metastatic cells.

LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.

Oncology, Nanomedicine, Drug delivery, Antibodies, Biosimilars, Active targeting, Intracellular, Oncoproteins, and Cytotoxics